Hualan Biological EngineeringInc (002007) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Hualan Biological Engineering Inc., together with its subsidiaries, engages in the research, development, production, and sale of biological products in China and internationally.
Total Cash From Operating Activities Chart for Hualan Biological EngineeringInc
Hualan Biological EngineeringInc (002007) operating cash flow for FY2025 was CNY 1.1B, a 7.8% change from FY2024. Hualan Biological EngineeringInc's operating cash flow grew from CNY 3.3M in 2003 to CNY 1.1B in 2025 (34028.2% over 22 years). Operating cash flow compound annual growth rate: 5-year CAGR of -2.9%, 10-year CAGR of 7.6%, 20-year CAGR of 13.0%.
Total Cash From Operating Activities (CNY)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ¥23.81B
- Implied Share Price
- ¥13.04
- Enterprise Value
- ¥21.06B
- Revenue (TTM)
- ¥4.36B
- EBITDA
- ¥1.23B
- Profit Margin
- 18.52%
- Trailing P/E
- 29.64
- Forward P/E
- 24.57
- Price/Book (MRQ)
- 2.16
- Price/Sales (TTM)
- 5.46
- EV/EBITDA
- 15.82
- EV/Revenue
- 4.77
- Dividend Yield
- 5.41%
- Book Value
- ¥6.01
- Free Cash Flow (FY2025)
- ¥944.67M
- Free Cash Flow Yield
- 3.97%
Snapshot as of 4th September 2026 — not point-in-time controlled, may lag the live market by a few days.